These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20965962)

  • 1. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis.
    Sternberg Z; Hennies C; Sternberg D; Bistulfi GL; Kazim L; Benedict RH; Chadha K; Leung C; Weinstock-Guttman B; Munschauer F
    Mult Scler; 2011 Feb; 17(2):157-63. PubMed ID: 20965962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.
    Pawlitzki M; Uebelhör J; Sweeney-Reed CM; Stephanik H; Hoffmann J; Lux A; Reinhold D
    Nutrients; 2018 Jul; 10(8):. PubMed ID: 30049983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum concentrations of pentosidine are related to presence and severity of coronary artery disease.
    Kerkeni M; Weiss IS; Jaisson S; Dandana A; Addad F; Gillery P; Hammami M
    Thromb Res; 2014 Sep; 134(3):633-8. PubMed ID: 25065554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
    Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
    Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis.
    Sternberg Z; Hennies C; Sternberg D; Wang P; Kinkel P; Hojnacki D; Weinstock-Guttmann B; Munschauer F
    J Neuroinflammation; 2010 Oct; 7():72. PubMed ID: 21034482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein.
    Senolt L; Braun M; Olejárová M; Forejtová S; Gatterová J; Pavelka K
    Ann Rheum Dis; 2005 Jun; 64(6):886-90. PubMed ID: 15897309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.
    Sternberg Z; Sternberg D; Drake A; Chichelli T; Yu J; Hojnacki D
    J Neuroimmunol; 2014 Sep; 274(1-2):197-201. PubMed ID: 25064498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.
    Sternberg Z; Weinstock-Guttman B; Hojnacki D; Zamboni P; Zivadinov R; Chadha K; Lieberman A; Kazim L; Drake A; Rocco P; Grazioli E; Munschauer F
    Mult Scler; 2008 Jul; 14(6):759-63. PubMed ID: 18505774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
    Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection.
    Scheijen JL; van de Waarenburg MP; Stehouwer CD; Schalkwijk CG
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Mar; 877(7):610-4. PubMed ID: 19188098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.
    Sugiyama S; Miyata T; Ueda Y; Tanaka H; Maeda K; Kawashima S; Van Ypersele de Strihou C; Kurokawa K
    J Am Soc Nephrol; 1998 Sep; 9(9):1681-8. PubMed ID: 9727377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure.
    Koyama Y; Takeishi Y; Arimoto T; Niizeki T; Shishido T; Takahashi H; Nozaki N; Hirono O; Tsunoda Y; Nitobe J; Watanabe T; Kubota I
    J Card Fail; 2007 Apr; 13(3):199-206. PubMed ID: 17448417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation.
    Hricik DE; Wu YC; Schulak A; Friedlander MA
    Clin Transplant; 1996 Dec; 10(6 Pt 1):568-73. PubMed ID: 8996781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma advanced glycosylation end-products in maintenance haemodialysis patients.
    Odetti P; Cosso L; Pronzato MA; Dapino D; Gurreri G
    Nephrol Dial Transplant; 1995 Nov; 10(11):2110-3. PubMed ID: 8643178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients.
    Slowick-Zylka D; Safranow K; Dziedziejko V; Dutkiewicz G; Ciechanowski K; Chlubek D
    J Nephrol; 2006; 19(1):65-9. PubMed ID: 16523428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
    Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
    Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
    Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
    Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.